Clinical trial
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily…
NCT00332202 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00332202 |
|---|---|
| Title | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin |
| Official title | A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | enzastaurin, placebo |
| Enrollment | 758 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Jun 1, 2006 |
| Last update posted | Sep 10, 2018 |
| Countries | Australia, Belgium, Brazil, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: